Predicting acute graft versus host disease using blood samples
Official title: CXC-chemokine Ligand 9 (CXCL9) and Endothelial Activation and Stress Index (EASIX) for Prediction of Acute Graft Versus Host Disease
Run by Henry Ford Health System · NCT05718791 · Data updated 2026-11-12
This study is trying to find specific markers in blood samples that can help predict if patients over 18 will develop severe acute graft versus host disease after receiving a stem cell transplant.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Henry Ford Health System Academic / other |
| Locations | 1 site (Detroit, Michigan) |
| Status | Recruiting |
| Started | May 10, 2023 |
| Main results expected | December 30, 2027 |
| Study ends | December 30, 2027 |
| Registry record updated | May 1, 2026 |
| Trial ID | NCT05718791 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years old who are being admitted for allogeneic stem cell transplantation for malignant diseases.
✕Probably not a fit
Patients who are under 18 years old or not undergoing allogeneic stem cell transplantation for malignant diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify immunologic signatures that can predict the onset of severe acute graft versus host disease (GVHD) in patients undergoing allogeneic stem cell transplantation. By analyzing blood samples from patients over 18 years old admitted for this procedure, the study seeks to uncover key biomarkers associated with clinical outcomes following different GVHD prophylaxis methods. Understanding these signatures could significantly enhance clinical decision-making and improve patient outcomes in stem cell transplantation.
Why it matters
Potential benefit: If successful, this study could lead to better prediction and management of acute GVHD, improving patient outcomes after stem cell transplantation.
How similar studies have gone: While the approach of predicting GVHD using immunologic signatures is being explored, this specific study's methodology may be novel and untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients \>18 year old admitted for allo SCT PB for malignant disease.
Where it's running
-
Henry Ford Health System
Detroit, Michigan, United States Recruiting
Study contacts
- Study coordinator: shatha farhan, MD
- Email: sfarhan1@hfhs.org
- Phone: 3137133910
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
First-line ruxolitinib plus corticosteroids for grade II acute graft-versus-host disease
This trial will test whether adding ruxolitinib to standard corticosteroids helps people with new grade II acute graft-versus-host disease after an allogeneic stem cell transplant.
-
Preventing GvHD in patients with blood cancers undergoing stem cell transplants
This study is testing a new treatment called TRX-103 to see if it can help prevent graft-versus-host disease in people with blood cancers who are getting stem cell transplants from mismatched donors.
-
Two-step ATG to prevent GVHD after myeloablative allogeneic stem cell transplant
This study tests whether a two-step dosing of rabbit ATG added to tacrolimus and low-dose methotrexate can help prevent severe acute and chronic GVHD in adults 18–60 receiving myeloablative allogeneic peripheral blood stem cell transplants for leukemia, MDS, or myeloproliferative disorders.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.